Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Heptares Inks R&D Deal with Pfizer; Pfizer to Buy 3% Stake in Sosei for US$33 Million
Sosei Group Corporation said on November 30 that its UK subsidiary Heptares Therapeutics has sealed an R&D collaboration pact with Pfizer Inc. involving G protein-coupled receptors (GPCRs), while also announcing a plan to raise US$33 million by allotting new shares…
To read the full story
Related Article
- Third GPCR-Targeted Drug Enters Clinic under Sosei/Pfizer Collaboration
May 20, 2021
- 2nd GPCR-Targeted Candidate Enters Clinic under Sosei/Pfizer’s Drug Discovery Alliance
September 29, 2020
- Sosei, Pfizer Nominate 3rd Development Candidate Compound
December 25, 2019
- Luring Big Pharma with GPCR Work, Sosei Heptares Treads Its Own Path to Pursue Small Molecule Targets
September 18, 2019
BUSINESS
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
- Linepharma to Rebrand as Nordic Pharma Japan from 2026
December 11, 2025
- Espha/Bayer Unit Add Pediatric Indication to Xarelto AG
December 11, 2025
- Enhertu’s PIII Ovarian Cancer Trial Kicks Off for 1st-Line Maintenance Therapy
December 11, 2025
- Pfizer Files Hympavzi for Hemophilia with Inhibitors
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…